Classifying risk factors for dyskinesia in Parkinson's disease.
BACKGROUND
Currently there is no classification of risk factors applicable to an individual patient with Parkinson's disease for the development of dyskinesia.


METHODS
We conducted literature search to identify and classifying risk factors into groups - (a) intrinsic vs extrinsic and (b) modifiable vs non-modifiable.


RESULTS
Younger age, young age of onset and severity of PD are major intrinsic non-modifiable risk factors for dyskinesia, female gender is another factor but not independent of other factors. Genetic expression and plasticity may determine pre-disposition to age of onset of PD and dyskinesia, these are currently non-modifiable factors arising due to an interaction of intrinsic and extrinsic factors. Lower initial body weight and weight loss during the course of the disease increase the risk of dyskinesia. Levodopa dose per kilogram body weight is a more significant risk factor than absolute levodopa dose. Early use of longer acting non-levodopa (i.e. dopamine agonists) medications delays the onset of dyskinesia. Interaction between body weight, levodopa dose and mode and duration of drug delivery is a significant modifiable factor.


CONCLUSIONS
Dyskinesia in PD arises as a consequence of the interaction of intrinsic versus extrinsic and modifiable versus non-modifiable factors. Identification and manipulation of modifiable factors for an individual patient may reduce the risk and burden of dyskinesia. Adjustment of levodopa dose according to body weight during the course of the disease seems to be a significant modifiable risk factor for dyskinesia.
Sharma
J C
JC
Consultant Physician and Honorary Professor, Sherwood Forest hospitals NHS Trust, University of Nottingham, UK. jagsharma@tiscali.co.uk
Bachmann
C G
CG
Linazasoro
G
G
D000367:Age Factors; D000978:Antiparkinson Agents / Q000009:adverse effects; D020820:Dyskinesias / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D008297:Male; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy; D012307:Risk Factors; D012737:Sex Factors
D000978:Antiparkinson Agents; D007980:Levodopa